Rheumatoid arthritis: Where are we now? Pathogenesis, treatment response and tailored therapy

Rheumatology (United Kingdom)

Volumn 51, Issue SUPPL.5, 2012, Pages

  Smolen, Josef ^a   Keystone, Edward C ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ALGORITHM; BIOLOGICAL THERAPY; CLINICAL PRACTICE; DISEASE ACTIVITY; EDITORIAL; HUMAN; IMMUNOPATHOGENESIS; MONOTHERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ARTHRITIS, RHEUMATOID; HUMANS;

EID: 84863858549     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes112     Document Type: Editorial

References (7)

1. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74.
2. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 2012;51(Suppl 5):3-11.
3. Pavelka K, Kavanaugh A, Rubbert A, Ferraccioli G. Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs. Rheumatology 2012;51(Suppl 5): 12-21.
4. Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology 2012;51(Suppl 5):22-30.
5. Gómez-Reino J. Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis. Rheumatology 2012;51(Suppl 5):31-37.
6. Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology 2012; 51(Suppl 5):38-47.
7. Keystone E, Smolen J, van Riel P. Developing an effective treatment algorithm for rheumatoid arthritis. Rheumatology 2012;51(Suppl 5):48-54.